Orphazyme A/S (ORPH)
| Market Cap | 485.96M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -64.09M |
| Shares Out | 34.66M |
| EPS (ttm) | -1.85 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 25 |
| Last Price | $13.84 |
| Previous Close | $13.65 |
| Change ($) | 0.19 |
| Change (%) | 1.39% |
| Day's Open | 13.78 |
| Day's Range | 13.04 - 13.84 |
| Day's Volume | 5,255 |
| 52-Week Range | 8.96 - 13.84 |
Orphazyme A/SInvestor news No. 01/2021 ...
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neuro...
Copenhagen, Denmark – December 27, 2020 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerati...
Orphazyme A/SCompany announcement No. 72/2020Inside informationCompany Registration No. 32266355
Global executive team expanding to support growth plans with three U.S.-based leaders
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neuro...
Orphazyme A/SCompany announcement No. 70/2020 ...
Orphazyme A/SCompany announcement No. 67/2020 ...
Due to unfortunate timing, Orphazyme listing on NASDAQ did not go smoothly.
Copenhagen, Denmark, October 2, 2020 – Orphazyme A/S (ORPHA; ORPH) (“Orphazyme”), CVR no. 32266355, a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the tr...
Orphazyme A/S has today registered a capital increase of new ordinary shares and completed its global offering, consisting of an initial public offering of American Depositary Shares (“ADSs”) ...
Orphazyme has filed to raise $100 million in a U.S. IPO.
Orphazyme A/SCompany announcement No. 50/2020 ...
Denmark-based Orphazyme A/S has filed to go public in the U.S., but has not yet determined how many shares it will offer.
About ORPH
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. The company was founded in 2009 and is headquartered in Copenhagen, Denmark.
| Industry Pharmaceutical Preparation Manufacturing | IPO Date Sep 29, 2020 |
| CEO Kim Stratton | Employees 114 |
| Stock Exchange NASDAQ | Ticker Symbol ORPH |
Analyst Forecasts
According to 3 analysts, the average rating for Orphazyme stock is "Strong Buy." The 12-month stock price forecast is 21.00, which is an increase of 51.73% from the latest price.